With respect to the latter, some evidence supports miR-29 (targeting, among several others, BCL2, IGF2BP1, VEGF) [16,17,18] involvement in each of the crucial cancer-progression mechanisms as well as for miR-122 (targeting, among others, p53 and MDM2) [67] and miR-1301 (targeting, among others, BCL9, VEGF, and β-catenin pathway) [68]. This evidence concerns the gene VEGFA and cancer.